# Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Source: https://onco.cc/trials/nct07793253/  
OnCo record `nct07793253` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of daraxonrasib in gallbladder cancer and other biliary tract cancers, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, not yet recruiting.

## Summary

Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer is a phase 2 interventional study registered as NCT07793253 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 55 participants, started 2026-11 and due to reach its primary completion in 2030-11. Interventions recorded: Daraxonrasib. Conditions listed: Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Ampulla of Vater Carcinoma, Ampullary Carcinoma. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07793253
- Phase: 2
- Setting: A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT07793253: https://clinicaltrials.gov/study/NCT07793253

## Connected records

- cancers: [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07793253.json